Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Ibrutinib associated with decreased circulating malignant cells and restored T-cell function in CLL patients
Key clinical point: Ibrutinib normalized abnormal immune cell counts to levels similar to those of age-matched healthy donors.
Major finding: Ibrutinib significantly restored T-cell proliferative ability, degranulation, and cytokine secretion.
Study details: Circulating counts of 21 immune blood cell subsets were compared between 55 patients with relapsed/refractory (R/R) CLLl and 50 previously untreated CLL patients, as compared with 20 untreated age-matched healthy donors.
Disclosures: The study was funded by Pharmacyclics, an AbbVie Company. Ms.. Solman is an employee of Translational Medicine, Pharmacyclics, Sunnyvale, Calif, as were several other authors.
Solman IG et al. Leuk Res. 2020;97: doi: 10.1016/j.leukres.2020.106432.